| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
β receptor
beta2-adrenergic receptor (agonist) |
|---|---|
| ln Vitro |
Clencyclohexerol is a beta-agonist and an analog of clenbuterol. beta-Adrenoceptor agonists, including clenbuterol, modulate protein synthesis and degradation and have therapeutic potential in muscle wasting disorders. Clencyclohexerol is a long-acting beta2-adrenergic receptor agonist with potent bronchodilatory and anabolic properties.
|
| ln Vivo |
Cellular activity data show that Clencyclohexerol acts as a beta-agonist, primarily by stimulating beta2-adrenergic receptors. This leads to smooth muscle relaxation and enhanced airflow in the respiratory tract. Additionally, it has anabolic effects that promote muscle growth and fat reduction, making it relevant for research into muscle wasting disorders and growth promotion.
|
| Enzyme Assay |
Radioligand binding assays for beta2-adrenoceptors are performed using membrane preparations from CHO cells expressing human beta2 receptors or rat lung membranes. [3H]-CGP12177 or [¹2⁵I]-cyanopindolol is used as the radioligand. Test compound is incubated with membranes at varying concentrations. Bound radioligand is separated by filtration and counted by scintillation. Ki values are calculated from competition curves to determine binding affinity.
|
| Cell Assay |
Cell-based functional assays for beta2-adrenergic agonism use CHO cells expressing human beta2 receptors with a cAMP response element reporter. Cells are seeded in 96-well plates and treated with serial dilutions of Clencyclohexerol. Agonist activity is measured by quantifying intracellular cAMP accumulation via HTRF or ELISA. EC50 is calculated from concentration-response curves. The effect on protein synthesis may be assessed in muscle cell lines.
|
| Animal Protocol |
In vivo animal studies for Clencyclohexerol typically involve oral or intravenous administration to rats or mice. Pharmacokinetic parameters are determined from blood samples collected at multiple time points. For growth promotion studies, animals are treated daily for 2-4 weeks and body weight, muscle mass, and feed efficiency are measured. Bronchodilatory effects are assessed in models of induced bronchospasm.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data specific to Clencyclohexerol are not fully characterized in the available literature. As a beta2-adrenoceptor agonist related to clenbuterol, it is expected to be orally bioavailable with moderate half-life and distribution to lung and muscle tissues. It may undergo metabolic clearance primarily via hepatic pathways.
|
| Toxicity/Toxicokinetics |
As a research compound, toxicity data for Clencyclohexerol are limited. Standard preclinical safety assessment would include acute and repeat-dose toxicity studies in rodents. beta-Agonists are known to cause cardiovascular effects including tachycardia, hypertension, and cardiac hypertrophy at high doses. The compound has been used as a growth promoter in farm animals, raising concerns about residue levels in meat products.
|
| References | |
| Additional Infomation |
Clencyclohexerol is a beta-adrenoceptor agonist and structural analog of clenbuterol. Its long-acting beta2-agonist properties give it potential therapeutic applications in asthma, COPD, and muscle wasting disorders. However, as of current information, it has not received regulatory approval for clinical use in humans. It has been used as a growth promoter in animals, but such use is restricted in many countries due to food safety concerns.
|
| Molecular Formula |
C14H20CL2N2O2
|
|---|---|
| Molecular Weight |
319.23
|
| Exact Mass |
318.09
|
| CAS # |
157877-79-7
|
| Related CAS # |
Clencyclohexerol-d10;1346599-61-8
|
| PubChem CID |
46783606
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
514.6±50.0 °C at 760 mmHg
|
| Flash Point |
265.0±30.1 °C
|
| Vapour Pressure |
0.0±1.4 mmHg at 25°C
|
| Index of Refraction |
1.621
|
| LogP |
1.74
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
20
|
| Complexity |
289
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1CC(CCC1NCC(C2=CC(=C(C(=C2)Cl)N)Cl)O)O
|
| InChi Key |
DKFLKXDTRUWFDL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H20Cl2N2O2/c15-11-5-8(6-12(16)14(11)17)13(20)7-18-9-1-3-10(19)4-2-9/h5-6,9-10,13,18-20H,1-4,7,17H2
|
| Chemical Name |
4-[[2-(4-amino-3,5-dichlorophenyl)-2-hydroxyethyl]amino]cyclohexan-1-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1325 mL | 15.6627 mL | 31.3254 mL | |
| 5 mM | 0.6265 mL | 3.1325 mL | 6.2651 mL | |
| 10 mM | 0.3133 mL | 1.5663 mL | 3.1325 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
